Articles by tag: hereditary-angioedema

Intellia CRISPR therapy: phase 3 data on edema — breakthrough

Intellia presented long-awaited phase III data of CRISPR therapy lonvo-z for hereditary angioedema: 87% reduction in attacks, 62% of patients attack-free. Learn about the breakthrough in in vivo genome editing.

CRISPR therapy in vivo: Intellia study 87% efficacy in HAE

Phase 3 HAELO: single CRISPR infusion reduced hereditary angioedema attacks by 87% vs placebo. First in vivo therapy on the verge of registration. Details, insights, forecasts.

In vivo gene editing: CRISPR therapy for hereditary angioedema

Single-dose CRISPR therapy NTLA-2002 reduced hereditary angioedema attacks by 87% in phase III. Learn how this will change treatment and pave the way to a cure.